Moderna's Phase 3 Flu Vaccine Trial Shows Promising Results for Licensure
Moderna's Phase 3 clinical trial for its flu vaccine has shown promising results.
The vaccine was found to be safe and effective in preventing influenza.
The trial involved over 10,000 participants across the US and Canada.
Moderna plans to submit the data to regulatory authorities for licensure.
The company hopes to have the vaccine available for the 2023-2024 flu season. Moderna plans to provide further updates on its reasearch and development during a virtual event with investors.
For more information